- Home
- IONS vs EXEL Comparison
IONS vs EXEL Comparison
Compare IONS & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IONS | EXEL |
|---|---|---|
| Founded | 1989 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1B | 12.7B |
| IPO Year | 1996 | 2000 |
Fundamental Metrics
Financial Performance| Metric | IONS | EXEL |
|---|---|---|
| Price | $41.55 | $70.89 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 25 | 17 |
| Target Price | ★ $84.13 | $59.79 |
| AVG Volume (30 Days) | ★ 2.5M | 2.3M |
| Earning Date | 11-13-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 21.71 | ★ 57.95 |
| EPS | N/A | ★ 2.46 |
| Revenue | N/A | ★ $452,477,000.00 |
| Revenue This Year | N/A | $10.16 |
| Revenue Next Year | $47.44 | $12.43 |
| P/E Ratio | ★ N/A | $28.34 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $42.08 | $37.58 |
| 52 Week High | $86.74 | $72.10 |
Technical Indicators
Market Signals| Indicator | IONS | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 36.99 | 83.32 |
| Support Level | N/A | $54.85 |
| Resistance Level | $46.14 | N/A |
| Average True Range (ATR) | 1.59 | 1.80 |
| MACD | 0.24 | 0.59 |
| Stochastic Oscillator | 3.15 | 87.36 |
Price Performance
Historical ComparisonAbout IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.